Although the dual inhibition of BRAF and MEK by their specific inhibitors has demonstrated significant treatment successes in advanced melanoma in patients with the BRAF mutation [12,13], most patients showed only short response durations along with the development of both intrinsic and acquired resistance [14]. The gene discussed is MAP2K7; the disease is melanoma.